A 12 month, multicenter, randomized, open-label study to evaluate safety and tolerability of everolimus with basiliximab and steroids in a maintained versus discontinued cyclosporine microemulsion based regimen in de novo kidney transplant recipients

Trial Profile

A 12 month, multicenter, randomized, open-label study to evaluate safety and tolerability of everolimus with basiliximab and steroids in a maintained versus discontinued cyclosporine microemulsion based regimen in de novo kidney transplant recipients

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs Ciclosporin; Everolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2011 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
    • 19 Aug 2010 Results from a pooled analysis (A2419 and A2423) were reported at the 23rd International Congress of the Transplantation Society.
    • 19 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top